Today's Research Daily features new research reports on 16 major stocks, including AbbVie Inc. (ABBV), Intel Corp. (INTC) and ...

Biopharmaceutical company AbbVie has reached an agreement with the Trump administration to invest $100 billion in its U.S.

Primarily known as an immunology and neuroscience company, AbbVie wanted to put the biopharma world on notice during its J.P.

AbbVie recently reported that Health Canada has approved MAVIRET (glecaprevir/pibrentasvir) for treating acute and chronic ...

Though far from the first large drugmaker to strike a pricing deal with the Trump administration, AbbVie’s new accord is ...

AbbVie has also pledged to participate in TrumpRx and offer many of its products, including Humira, on a direct-to-patient ...

As with the many other “most-favored-nation” deals between the White House and large pharmas, the agreement is short on ...

AbbVie continues to project low single-digit growth through 2030 as it expands its immunology franchise and makes a major ...

AbbVie reached a deal with the Trump administration on drug prices in exchange for being exempted from tariffs and future ...

The Trump administration has finalized a deal with drugmaker AbbVie to cut the cost of certain medicines, marking the latest ...

Hold iShares U.S. Healthcare ETF (IYH): top holdings face GLP-1 risks, patent cliffs and high valuations. Read here for an ...

The first two days of the J.P. Morgan Healthcare Conference are in the books, and attendees are now pushing through to finish ...